Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison
Shuyan Gu,Xiaoqian Hu,Xuemei Zhen,Lizheng Shi,Xueshan Sun,Minzhuo Huang,Yuxuan Gu,Yuanyuan Li,Hengjin Dong
DOI: https://doi.org/10.2139/ssrn.3918870
2021-01-01
SSRN Electronic Journal
Abstract:Background: There are multiple alternative glucose-lowering drugs available as initial monotherapy for patients with type 2 diabetes (T2DM) with contraindications or intolerance of metformin. However, little systematic and comparative data is available for them as initial monotherapy. We compared the efficacy and safety of them as monotherapy for T2DM. Methods: In this systematic review and indirect treatment comparison, PubMed, Embase, Web of Science, CNKI, WanFang Data, and Chongqing VIP were searched for randomized controlled trials (1990-2020) comparing a glucose-lowering drug monotherapy with placebo (or lifestyle-intervention) in adult T2DM patients. The drug classes included metformin, SUs, TZDs, glinides, AGIs, DPP-4is, SGLT2is, GLP-1RAs, and insulins. The drugs were firstly compared with placebo/lifestyle-intervention using meta-analysis, then compared against each other using indirect treatment comparison. Weighted mean difference with 95% CIs were calculated for HbA1c, FPG, BMI, TC, HDL-C, and SBP. Relative risk with 95% CIs were calculated for hypoglycemia. This study is registered with PROSPERO (CRD42020170769). Findings: 185 studies assessing 23 drugs from eight drug classes were included (no eligible study was found for insulin). SUs were most efficacious in reducing HbA1c and FPG but increased hypoglycemic risks. Metformin was most efficacious in lowering BMI. GLP-1RAs were most efficacious in reducing TC. TZDs were most efficacious in increasing HDL-C. SGLT2is were most efficacious in lowering SBP. Overall, GLP-1RAs comprehensively controlled HbA1c, FPG, BMI, TC, and SBP, whilst metformin controlled HbA1c, FPG, BMI, TC, and HDL-C, and both of them did not increase hypoglycemic risks. Our observations also showed that although drug class is important, drugs within the same class may display important differences in treatment effects. Interpretation: Our results, along with individualized patient characteristics, preferences, and clinical needs, should be considered when selecting a drug as monotherapy for T2DM in clinical practice. Funding: National Natural Science Foundation of China.Declaration of Interest: None to declare.